|
|
|
|
|
|
|
|
QCMD Past EQA panels available from Argene. This page is intended for Argene customers use only.
|
|
| Product Range |
|
|
| Last updated:13/02/2012
|
|
| Product Code |
Description |
Price Code |
|
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
Frozen virus transport medium (VTM) |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured / Clinical / Purified Nucleic Acid |
| Panel Format |
Physiological solution |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
|
|
|
|
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured or Clinical |
| Panel Format |
"Plasma, Frozen Liquid" |
| Measurement |
IU/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Clinical virus |
| Panel Format |
Frozen Plasma |
| Measurement |
IU/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Clinical virus |
| Panel Format |
Frozen Plasma |
| Measurement |
IU/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured / Clinical material |
|
|
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
|
|
|
|
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured bacteria |
| Panel Format |
Frozen physiological saline |
|
|
| Panel Member Target Range |
Covering clinical range |
|
|
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured bacteria |
| Panel Format |
Physiological solution |
| Measurement |
CFU/ml |
| Panel Member Target Range |
Covering clinical range |
|
|
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured bacteria |
| Panel Format |
Physiological solution |
| Measurement |
CFU/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0ml |
| Panel Sample Pre-treatment requirements. |
Ready for Analysis |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Bacteria |
| Panel Format |
Culture medium |
| Measurement |
CFU/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0ml |
| Panel Sample Pre-treatment requirements. |
DNA extraction |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured bacteria |
| Panel Format |
Lyophilised culture medium |
| Measurement |
CFU/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured bacteria |
| Panel Format |
Lyophilised culture medium |
| Measurement |
CFU/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured bacteria |
| Panel Format |
Lyophilised culture medium |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cytomegalovirus |
| Panel Format |
"Citrate plasma, freeze dried" |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution with NAT grade H2O |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured or Clinical |
| Panel Format |
"Plasma, Freeze-dried" |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured or Clinical |
| Panel Format |
"Plasma, Freeze-dried" |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
"Lyophilised Plasma, Virus Transport Medium (VTM), Whole Blood" |
| Measurement |
IU/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured CMV |
| Panel Format |
Whole blood |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
|
|
| Panel Sample Pre-treatment requirements. |
Standard DNA extraction |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
|
|
| Sample / Nucleic Acid Target Source |
Cultured virus and clinical material |
| Panel Format |
Whole blood on DBS collection card |
|
|
| Panel Member Target Range |
Covering clinical range |
|
|
| Panel Sample Pre-treatment requirements. |
DNA extraction from dried blood spot |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
Whole blood on DBS collection card |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
|
|
| Panel Sample Pre-treatment requirements. |
DNA extraction from dried blood spot |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured bacteria |
| Panel Format |
Lyophilised bronchoalveolar lavage (BAL) or sample transport |
|
|
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
0.5 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured Chlamydia trachomatis |
| Panel Format |
Freeze dried urine or Freeze dried 1/10 TE buffer |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution in sterile water |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
4°C / ambient shipment |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured Chlamydia trachomatis |
| Panel Format |
Freeze dried urine or Freeze dried 1/10 TE buffer |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
N/A |
| Panel Sample Pre-treatment requirements. |
Reconstitution |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Amplicor Cobas ( Roche) ;Probe TEC (BD) ; Gen Probe TMA Quantitative real time |
| Storage / shipment conditions |
4°C / ambient shipment |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured Chlamydia trachomatis |
| Panel Format |
"Urine or PBS, Freeze-dried" |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured Chlamydia trachomatis |
| Panel Format |
"Urine or PBS, Freeze-dried" |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured Chlamydia trachomatis |
| Panel Format |
Freeze-dried Urine or PBS |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured Chlamydia trachomatis |
| Panel Format |
Freeze-dried Urine or Simulated Swab |
| Measurement |
Copies/vial |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured Chlamydia trachomatis |
| Panel Format |
Freeze-dried Urine or Simulated Swab |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured bacteria |
| Panel Format |
Lyophilised Urine or Physiological Buffer |
| Measurement |
Copies/vial |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured bacteria |
| Panel Format |
Lyophilised Urine or Physiological Buffer |
| Measurement |
Copies/vial |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured bacteria |
| Panel Format |
Lyophilised Urine or Physiological Buffer |
| Measurement |
Copies/vial |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
2.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured bacteria |
| Panel Format |
Lyophilised Urine or Physiological Buffer |
| Measurement |
Copies/vial |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
Frozen virus transport medium (VTM) |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering Clinical Range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Cultured Virus |
| Panel Format |
Lyophilised virus transport medium (VTM) |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Epstein Barr virus (EBV) |
| Panel Format |
Plasma / patient samples |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Standard NA Extraction protocol |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Epstein Barr virus (EBV) |
| Panel Format |
Cultured EBV in FCS / DMEM |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Standard NA Extraction protocol |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured |
| Panel Format |
"DMEM / FCS, Temperature stable liquid" |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Samples are ready for analysis and should be treated as clinical samples and ana |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
Lyophilised VTM |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
"Lyophilised Plasma, Virus Transport Medium (VTM), Whole Blood" |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
Lyophilised VTM |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
Lyophilised virus transport medium (VTM) |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
HBV (various subtypes) |
| Panel Format |
Serum |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Standard Extraction protocol for both commercial as well as in-house development |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
HBV (various subtypes) |
| Panel Format |
Serum |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Standard Extraction protocol for both commercial as well as in-house development |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
"HBV genotype A HBV genotype D, both from chronical" |
| Panel Format |
Serum/Plasma |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Standard Extraction protocol for both commercial as well as in-house development |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured or Clinical |
| Panel Format |
"Plasma, Frozen Liquid" |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Samples are ready for analysis and should be treated as clinical samples and ana |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured or Clinical |
| Panel Format |
"Plasma, Frozen Liquid" |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treated as clinical samples and analysed accordingly. |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Clinical |
| Panel Format |
"Serum, Frozen Liquid" |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treated as clinical samples and analysed accordingly. |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured virus or Clinical material |
| Panel Format |
Frozen Plasma |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Clinical material |
| Panel Format |
Frozen Plasma |
| Measurement |
IU/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
Genotype |
| Sample / Nucleic Acid Target Source |
Clinical |
| Panel Format |
"Plasma, Frozen Liquid" |
|
|
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treated as clinical samples and analysed accordingly. |
| Panel Suitability |
Genotypic |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
Genotype |
| Sample / Nucleic Acid Target Source |
Cultured virus or Clinical material |
| Panel Format |
Frozen Plasma |
|
|
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly |
| Panel Suitability |
Molecular typing |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
Genotype |
| Sample / Nucleic Acid Target Source |
Cultured virus or Clinical material |
| Panel Format |
Frozen Plasma |
|
|
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly |
| Panel Suitability |
Molecular typing |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
Genotype |
| Sample / Nucleic Acid Target Source |
Clinical material |
| Panel Format |
Frozen Plasma |
|
|
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly |
| Panel Suitability |
Molecular typing |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
HCV (various Subtypes) |
| Panel Format |
EDTA Plasma |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Clinical material |
| Panel Format |
Frozen Plasma |
| Measurement |
IU/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Clinical material |
| Panel Format |
Frozen Plasma |
| Measurement |
IU/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Clinical material |
| Panel Format |
Frozen Plasma |
| Measurement |
IU/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
Genotype |
| Sample / Nucleic Acid Target Source |
Plasma/RNA |
|
|
| Measurement |
IU/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
- |
| Panel Suitability |
Genotypic |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
Genotype |
| Sample / Nucleic Acid Target Source |
Cultured or Clinical |
| Panel Format |
"Plasma, Frozen Liquid" |
|
|
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Samples are ready for analysis and should be treated as clinical samples and ana |
| Panel Suitability |
Genotypic |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
Genotype |
| Sample / Nucleic Acid Target Source |
Cultured or Clinical |
| Panel Format |
"Plasma, Frozen Liquid" |
|
|
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Genotypic |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
Genotype |
| Sample / Nucleic Acid Target Source |
Clinical |
| Panel Format |
"Plasma, Frozen Liquid" |
|
|
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Genotypic |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
Genotype |
| Sample / Nucleic Acid Target Source |
Clinical material |
| Panel Format |
Frozen Plasma |
|
|
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Molecular typing |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
Genotype |
| Sample / Nucleic Acid Target Source |
Clinical material |
| Panel Format |
Frozen Plasma |
|
|
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Molecular typing |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
Genotype |
| Sample / Nucleic Acid Target Source |
Clinical material |
| Panel Format |
Frozen Plasma |
|
|
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Molecular typing |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
Genotype |
| Sample / Nucleic Acid Target Source |
Clinical material |
| Panel Format |
Frozen Plasma |
|
|
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Molecular typing |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured Human Herpes Virus 6 |
| Panel Format |
Lyophilised Plasma |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured Human Herpes Virus 6 |
| Panel Format |
Lyophilised Plasma or Viral Transport Medium |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
Lyophilised Plasma or Virus Transport Medium (VTM) |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Leucocytes |
| Panel Format |
Cell Pellet |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
N/A |
| Panel Sample Pre-treatment requirements. |
Standard Extraction protocol for both commercial as well as in-house development |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured |
| Panel Format |
"PBMC Pellet, Frozen Pellet" |
| Measurement |
DNA Copies/Sample |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
N/A |
| Panel Sample Pre-treatment requirements. |
Samples are ready for analysis and should be treated as clinical samples and analysed accordingly |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured |
| Panel Format |
"PBMC Pellet, Frozen Pellet" |
| Measurement |
DNA Copies/Sample |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
N/A |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured or Clinical |
| Panel Format |
"PBMC Pellet, Frozen Pellet" |
| Measurement |
DNA Copies/Sample |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
N/A |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured proviral cells |
| Panel Format |
Frozen PBMC in buffer |
| Measurement |
DNA Copies/Sample |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
0.1ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured proviral cells |
| Panel Format |
Frozen PBMC in buffer |
| Measurement |
DNA Copies/Sample |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
0.1ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured proviral cells |
| Panel Format |
Frozen PBMC in buffer |
| Measurement |
DNA Copies/Sample |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
0.1 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured proviral cells |
| Panel Format |
Frozen PBMC in buffer |
| Measurement |
DNA Copies/Sample |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
0.1 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
Drug Resistance Typing |
| Sample / Nucleic Acid Target Source |
Cultured or Clinical |
| Panel Format |
"Plasma, Freeze-dried" |
|
|
| Panel Member Target Range |
Various mutations - Reverse Transcriptase (RT) and Protease (PR) genes |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution |
| Panel Suitability |
Sequencing |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
Drug Resistance Typing |
| Sample / Nucleic Acid Target Source |
Cultured or Clinical |
| Panel Format |
"Plasma, Freeze-dried" |
|
|
| Panel Member Target Range |
Various mutations - Reverse Transcriptase (RT) and Protease (PR) genes |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution |
| Panel Suitability |
Sequencing |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
Drug Resistance Typing |
| Sample / Nucleic Acid Target Source |
Cultured virus or Clinical material |
| Panel Format |
Lyophilised Plasma |
|
|
| Panel Member Target Range |
Various mutations - Reverse Transcriptase (RT) and Protease (PR) genes |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Sequencing |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
Drug Resistance Typing |
| Sample / Nucleic Acid Target Source |
Cultured virus or Clinical material |
| Panel Format |
Lyophilised Plasma |
|
|
| Panel Member Target Range |
Various mutations - Reverse Transcriptase (RT) and Protease (PR) genes |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Sequencing |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
Drug Resistance Typing |
| Sample / Nucleic Acid Target Source |
Cultured virus or Clinical material |
| Panel Format |
Lyophilised Plasma |
|
|
| Panel Member Target Range |
Various mutations - Reverse Transcriptase (RT) and Protease (PR) genes |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Sequencing |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
Drug Resistance Typing |
| Sample / Nucleic Acid Target Source |
Cultured virus or Clinical material |
| Panel Format |
Lyophilised Plasma |
|
|
| Panel Member Target Range |
Various mutations - Reverse Transcriptase (RT) and Protease (PR) genes |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Sequencing |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
Drug Resistance Typing |
| Sample / Nucleic Acid Target Source |
Cultured virus or Clinical material |
| Panel Format |
Lyophilised Plasma |
|
|
| Panel Member Target Range |
Various mutations - Integrase (INT) gene |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Sequencing |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
HIV-1 (various Subtypes) |
| Panel Format |
EDTA Plasma |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
HIV-1 (various Subtypes) |
| Panel Format |
EDTA Plasma |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Cultured or Clinical |
| Panel Format |
"Plasma, Frozen Liquid" |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Cultured virus or Clinical material |
| Panel Format |
Frozen Plasma |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Cultured virus or Clinical material |
| Panel Format |
Frozen Plasma |
| Measurement |
IU/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
Lyophilised VTM |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
0.5 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
Lyophilised VTM |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
Frozen virus transport medium (VTM) |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
|
|
| Sample / Nucleic Acid Target Source |
Cultured material from human and animal origin |
| Panel Format |
DMEM / FCS |
|
|
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
0.5 ml |
| Panel Sample Pre-treatment requirements. |
Routine laboratory procedures |
| Panel Suitability |
Qualitative & Genotypic |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
|
|
| Sample / Nucleic Acid Target Source |
Cultured material from human and animal origin |
| Panel Format |
Frozen VTM |
|
|
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
0.5 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative & Genotypic |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
|
|
| Sample / Nucleic Acid Target Source |
Cultured material from human and animal origin |
| Panel Format |
Frozen VTM |
|
|
| Panel Member Target Range |
Covering clinical range |
|
|
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative & Genotypic |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
|
|
| Sample / Nucleic Acid Target Source |
Cultured virus or clinical material |
| Panel Format |
Frozen VTM |
|
|
| Panel Member Target Range |
Covering clinical range |
|
|
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Molecular typing |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
Frozen virus transport medium (VTM) |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly |
| Panel Suitability |
Molecular typing |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Clinical or Cultured virus |
| Panel Format |
Lyophilised VTM or plasma |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Clinical material or Cultured virus |
| Panel Format |
Lyophilised virus transport medium (VTM) or plasma |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Legionella pneumophila sg 1 |
| Panel Format |
"Bronchoalveolar lavage (BAL), Phosphate buffer (PB)" |
| Measurement |
CFU/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
0.5 ml |
| Panel Sample Pre-treatment requirements. |
Routine laboratory procedures |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
'in-house' and commercial Leg diagnostic protocols |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured bacteria |
| Panel Format |
Bronchoalveolar lavage(BAL) or physiological soln. |
|
|
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
0.5 ml |
| Panel Sample Pre-treatment requirements. |
Routine laboratory procedures |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured bacteria |
| Panel Format |
BAL or physiological solution |
|
|
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
0.5 ml |
|
|
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured bacteria |
| Panel Format |
Bronchoalveolar lavage (BAL) or sample transport medium |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
0.5 ml |
|
|
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
Frozen virus transport medium (VTM) |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Inactivated cultured MRSA |
| Panel Format |
Culture Medium |
|
|
| Panel Member Target Range |
covering clinical range |
| Panel Member Sample Volume(ml) |
1.0ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Inactivated cultured MRSA |
| Panel Format |
Culture Medium |
| Measurement |
CFU/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Inactivated cultured MRSA |
| Panel Format |
Culture Medium |
| Measurement |
CFU/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Inactivated cultured MRSA |
| Panel Format |
Culture Medium |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.2 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly. |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured |
| Panel Format |
"Sputum, Temperature stable liquid" |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
250 µl |
| Panel Sample Pre-treatment requirements. |
Decontamination |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured |
| Panel Format |
Sputum or protein rich buffer |
| Measurement |
Cells/Sample |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
250 µl |
| Panel Sample Pre-treatment requirements. |
Routine respiratory sample treatment |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured |
| Panel Format |
Sputum or protein rich buffer |
| Measurement |
Cells/Sample |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
250 ul |
| Panel Sample Pre-treatment requirements. |
Routine respiratory sample treatment |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured Mycobacteria tuberculosis Complex |
| Panel Format |
Sputum or protein rich buffer |
| Measurement |
Cells/Sample |
| Panel Member Target Range |
Covering clinical range |
|
|
| Panel Sample Pre-treatment requirements. |
Routine respiratory sample treatment |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured Mycobacteria tuberculosis Complex |
| Panel Format |
Sputum or protein rich buffer |
|
|
| Panel Member Target Range |
Covering clinical range |
|
|
| Panel Sample Pre-treatment requirements. |
Routine respiratory sample treatment |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured Mycobacteria tuberculosis Complex |
| Panel Format |
Sputum or protein rich buffer |
|
|
| Panel Member Target Range |
Covering clinical range |
|
|
| Panel Sample Pre-treatment requirements. |
Routine respiratory sample treatment |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured Mycobacteria tuberculosis Complex (BCG) |
| Panel Format |
Sputum or protein rich buffer |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
0.25 ml |
| Panel Sample Pre-treatment requirements. |
Routine respiratory sample treatment |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
urine |
| Panel Format |
Freeze dried urine |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.6ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured |
| Panel Format |
"Urine, Freeze-dried" |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.6ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured bacteria |
| Panel Format |
Lyophilised Urine |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.6ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured bacteria |
| Panel Format |
Lyophilised Urine or Physiological Buffer |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.6 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured bacteria |
| Panel Format |
Lyophilised Urine |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.6 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Cultured Virus |
| Panel Format |
Clinical Substitute |
|
|
| Panel Member Target Range |
Covering clinical range |
|
|
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Cultured whole virus or RNA Transcripts |
| Panel Format |
Frozen VTM or Buffer |
|
|
| Panel Member Target Range |
Covering clinical range |
|
|
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical or semi-processed samples |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Cultured whole virus or RNA Transcripts |
| Panel Format |
Frozen virus transport medium (VTM) of buffer |
| Measurement |
Copies/ml |
|
|
| Panel Member Sample Volume(ml) |
"1.0ml VTM, 0.1ml Buffer" |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical or semi-processed samples |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured / Clinical material |
|
|
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
|
|
|
|
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
Lyophilised virus transport medium (VTM) |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
Frozen VTM |
|
|
| Panel Member Target Range |
Covering Clinical Range. |
| Panel Member Sample Volume(ml) |
1.0ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
Frozen virus transport medium (VTM) |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering Clinical Range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
Frozen virus transport medium (VTM) |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Cultured virus material |
| Panel Format |
DMEM / FCS (10%) |
|
|
| Panel Member Target Range |
Covering clinical range. |
| Panel Member Sample Volume(ml) |
1.0ml |
|
|
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
Frozen VTM |
|
|
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
Frozen VTM |
|
|
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
Frozen virus transport medium (VTM) |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Ready for analysis. Treat as clinical samples and analyse accordingly |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
<-20°C / Dry-ice |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Strains collected from In vitro culture Reference |
| Panel Format |
Amniotic fluid |
| Measurement |
Units |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured T. gondii |
| Panel Format |
Lyophilised Amniotic fluid or Plasma |
| Measurement |
Tg Units/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
2.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured T. gondii |
| Panel Format |
Lyophilised amniotic fluid or plasma |
| Measurement |
Tg Units/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
2.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
VZV Strain Ellen (ATCC) VZV Strain 9/84 (SMI) |
| Panel Format |
Lyophilised cultured VZV |
| Measurement |
Geq/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml (after reconstitution) |
| Panel Sample Pre-treatment requirements. |
Reconstitution in sterile water |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
'in-house' and commercial VZV diagnostic protocols |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured |
| Panel Format |
"DMM / BSA, Freeze-dried" |
| Measurement |
Geq/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution |
|
|
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured |
| Panel Format |
"DMM / BSA, Freeze-dried" |
| Measurement |
Geq/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured |
| Panel Format |
"DMM / BSA, Freeze-dried" |
| Measurement |
Geq/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
Lyophilised VTM |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
Lyophilised VTM |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
Lyophilised VTM |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
DNA |
| Sample / Nucleic Acid Target Source |
Cultured virus |
| Panel Format |
Lyophilised virus transport medium (VTM) |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.1 ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative & Quantitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Cultured Virus |
| Panel Format |
Lyophilised plasma or VTM |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
"Evaluated by commercial, In-house & 'Real-time' NAT" |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
| Feature | Specifications |
| Sample / Nucleic Acid Target type |
RNA |
| Sample / Nucleic Acid Target Source |
Cultured Virus |
| Panel Format |
Lyophilised virus transport medium (VTM) |
| Measurement |
Copies/ml |
| Panel Member Target Range |
Covering clinical range |
| Panel Member Sample Volume(ml) |
1.0ml |
| Panel Sample Pre-treatment requirements. |
Reconstitution of lyophilised material |
| Panel Suitability |
Qualitative |
| Panel QC Reference Testing |
Evaluated by various molecular methodologies |
| Storage / shipment conditions |
2-8°C / Ambient |
| |
|
|
|
|
|
|
|
|
|
